Article
New Arguments In Momenta On Standing To Appeal IPR Loss Before Filing A Biosimilar Application
In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Co., No. 17-1694 (Fed. Cir. argued Dec. 5, 2017), BMS challenges Momenta's standing to appeal a PTAB decision upholding the validity of BMS's patent ...
Patterson Belknap Webb & Tyler LLP
